Sage touts pos­i­tive ear­ly sig­nals in Alzheimer's. Will they be able to re­peat it in a blind­ed study?

Sage Ther­a­peu­tics on Fri­day un­corked what it sees as some pos­i­tive — al­beit ear­ly, and un­blind­ed — da­ta sug­gest­ing its lead neu­ropsy­chi­atric drug led to im­prove­ments in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER